^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Androgen receptor degrader

    Related drugs:
    5d
    Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer. (PubMed, J Med Chem)
    This compound inhibited AR signaling in vitro and was able to inhibit tumor growth in vivo in a mouse prostate cancer xenograft model. Extensive profiling in terms of drug-like properties allowed this to be progressed into development as AZD9750.
    Journal
    |
    AR (Androgen receptor)
    21d
    ANDROMEDA: A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs (clinicaltrials.gov)
    P1/2, N=300, Not yet recruiting, AstraZeneca
    New P1/2 trial • First-in-human
    |
    saruparib (AZD5305)
    21d
    A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer (clinicaltrials.gov)
    P2, N=30, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial
    |
    Firmagon (degarelix)
    22d
    A Phase I Study of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=15, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    luxdegalutamide (ARV-766)
    1m
    A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants (clinicaltrials.gov)
    P1, N=42, Recruiting, Celgene | Not yet recruiting --> Recruiting
    Enrollment open
    |
    itraconazole • rifampicin
    1m
    CC-94676-PCA-001: Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=131, Completed, Celgene | Active, not recruiting --> Completed | N=250 --> 131 | Trial completion date: Dec 2026 --> Oct 2025
    Trial completion • Enrollment change • Trial completion date
    1m
    A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients (clinicaltrials.gov)
    P1/2, N=84, Recruiting, Hinova Pharmaceuticals Inc. | Trial primary completion date: Oct 2025 --> Mar 2026
    Trial primary completion date
    2ms
    Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration (clinicaltrials.gov)
    P1, N=64, Completed, AnHorn Medicines Co. Ltd. | Recruiting --> Completed
    Trial completion
    2ms
    A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, Celgene
    New P1 trial
    |
    itraconazole • rifampicin
    3ms
    A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Dec 2026 --> Jun 2027 | Trial primary completion date: Sep 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    docetaxel • abiraterone acetate • prednisone • zeprumetostat (SHR-2554) • HRS-5041 • M9466
    3ms
    A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=210, Recruiting, Genentech, Inc. | Trial completion date: Jul 2026 --> Jun 2027 | Trial primary completion date: Jul 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    4ms
    An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) (clinicaltrials.gov)
    P1/2, N=188, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    tulmimetostat (DZR123) • luxdegalutamide (ARV-766)